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Background: Assessing patient’s perspective provides useful information enabling a customized
approach which has been advocated by current guidelines. In this multicentre cross-sectional
study we evaluated personal viewpoints on allergen-specific immunotherapy (SIT) in patients
treated with subcutaneous (SCIT) or sublingual (SLIT) immunotherapy.
Methods: A survey of 28 questions assessing patient’s knowledge, perceptions, expectations
and satisfaction was developed by an expert panel and was applied by physicians from aller-
gology centres in patients with respiratory allergy treated with SIT. Treating physicians inde-
pendently reported their satisfaction level regarding SIT for each patient.
Results: Fully completed surveys from 434 patients (55.3% male; 66.7% poly-sensitized, 74%
SLIT) were analysed. Mean duration of SIT was 2.5 years with different allergens. Most patients
acquired their SIT knowledge from their physician (95%) and consequently, their physicians’
opinion in their choice to start with SIT was important. Most patients perceived SIT to be safersity Lund, Department of Respiratory Diseases and Allergology, Lund, Sweden.
emon.nl (Z. Diamant).
(see Appendix A).
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362 I. Baiardini et al.and easy to integrate into their daily routine. The main motivations for SIT were its supposed
potential to alter the course of the disease (45.7%), less need of (28.2%), or dissatisfaction with
current pharmacotherapy (19.3%). Both patients’ and physicians’ satisfaction was high (VAS-
scores 74/100 and 78/100, respectively) and showed a significant correlation (SCIT:
rZ 0.612; SLIT: rZ 0.608). No major difference was found in patients’ answers based on
the level of education.
Conclusion: In this real life study evaluating different aspects of patient’s perspective on SIT,
the majority of patients had an adequate level of knowledge, perceptions, expectations and
satisfaction about SIT, which corresponded well with the physician’s perceptions and satisfac-
tion. Our data warrant the use of patient’s perspectives on chronic SIT treatment.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Assessing patient’s personal viewpoints on disease activity
and treatment provides useful information enabling
a customized therapeutic approach.1 The pivotal role of
patient’s perspectives is now advocated by the Grade of
Recommendations, Assessment, Development and Evalua-
tion (GRADE) system,2 recently adopted by the World
Health Organization (WHO), as a guideline for both quality
of evidence and strength of recommendations. Along with
traditional parameters of safety and efficacy, this system
also includes patient’s preferences and values as corner-
stones in the development of recommendations for thera-
peutic interventions, thus enabling the translation of
scientific research into real life.2 Several aspects of
allergen-specific immunotherapy (SIT) for the treatment of
allergic rhinitis have been extensively investigated,
including clinical efficacy,3 tolerability,4 effects on health-
related quality of life (HRQoL)4e6 and cost-effectiveness.7
However, besides HRQoL assessment, only few studies
addressing patient’s perspective on this treatment modality
have been published.8e10 In these studies, the population
size was relatively small and the surveys took into account
only one administration mode. This precludes a more
general applicability of these findings.
The aim of the present multicentre cross-sectional
survey was to explore the patients’ subjective viewpoint
on SIT including knowledge, perceptions, expectations and
satisfaction in a large cohort of patients treated with either
subcutaneous (SCIT) or sublingual immunotherapy (SLIT). In
addition, the physicians’ viewpoint (in terms of satisfaction
and perceptions) and its association to the patients’
perspectives were also explored.
Materials and methods
A cross-sectional observational survey was conducted across
13 specialized medical centres in North Italy from March to
September 2010. Thirteen physicians with experience in
immunotherapy treatment (allergologists, pulmonologists,
dermatologists, pediatricians) invited 35 consecutive
patients with allergic rhinitis with or without concomitant
asthma treated with SIT to fill out a questionnaire related to
their knowledge, perceptions, expectations and satisfaction
of their treatment with SIT. Patients were invited to answer
28 questions while waiting for their control visit. The
treating physicians were requested to collect clinical data of
all participating patients (including disease severity, allergysensitization, type of SIT). In addition, all physicians
answered 3 questions related to their own satisfaction with
the respective SIT for each patient enrolled in the survey.
Both the patient and the physician were requested to
complete the survey independently. The study was con-
ducted in accordance with national legislation pertaining to
confidentiality and data protection.
Patients
In all, 455 patients with allergic rhinitis with or without
concomitant asthma treated with SIT (PURETHAL or SUB-
LIVAC HAL Allergy BV, Leiden, The Netherlands) were
invited to participate in the survey. The inclusion criteria
comprised the comprehension of written and spoken Italian
language and the availability to participate in the survey.
Exclusion criteria were the presence of evidently impaired
cognitive functions and visual-auditory deficit and/or
a physical inability to autonomously answer the questions.
Surveys
The questionnaires were developed by an expert panel on
the basis of experience and literature review.11e13 Prior to
application, the questionnaire was tested by 10 patients
and 5 physicians to ensure the word choice and content of
the questions were widely understood.
The patient questionnaire consisted of 28 items evaluating
the knowledge (6 questions), perceptions (12 questions),
expectations (5 questions) and satisfaction (5 questions)
regarding SIT. There were 20 multiple choice and yes/no
questions (where the patient had to choose 1 answer among
those indicated) and 8 visual analogue scale (VAS) questions
(where the answer had to be indicated on a 10 cm horizontal
scale ranging from 0 e not at all e to 100 e very much).
The physician questionnaire documented the physician’s
satisfaction with the therapeutic efficacy of the SIT in each
enrolled patient, whether there had been a change in the
clinical condition since the start of SIT and if, in retrospect,
he/she would prescribe the same type of SIT. Both ques-
tionnaires are presented in the Online Supplementary
Material (Appendix B).
Statistical analyses
It was planned to include 35 patient questionnaires from all
participatingphysicians.Descriptive statisticswereperformed
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answers to the questions. In addition, the following analyses
were performed with the aim to evaluate:
- potential association between patients’ education level
(primary school and secondary schoolZ low education
level; high school, academic degree and post-
graduateZ high education level) and answers given to
the survey and potential differences in answers
between the two treatment modalities (SCIT and SLIT)
(Chi square test); and
- correlation and concordance among patients’ and
physicians’ answers (Spearman Rho correlation,
Cohen’s Kappa coefficient).
Results
Of the 455 patients invited, 449 patients filled in the
questionnaire. Only the questionnaires with more than
a 95% completion rate (434) were considered for analysis.
Patient demographics, clinical data and duration of SIT
are provided in Table 1.
The most frequently administered allergens were grass
pollen (37.1%) followed by mites (26.6%), tree pollen (17%),Table 1 Patient demographics and clinical data.
Demographic characteristics (nZ 434)
Gender 238 Males/192
Females
Mean age SD in years (range) 31.5 12.2
(age range: 18e54)
Mean duration of treatment SD
in years (range)
2.5 1.3 (0e9)
Highest level of education
Primary school (%) 6.2
Secondary school (%) 15.2
High school (%) 50.7
Academic degree (%) 6.7
Postgraduate (%) 20.2
Clinical data




Moderate e Severe (%) 88.7










SLIT (%) 74weed and flower pollen (9.2%), moulds (5.6%), epithelia
(2%) and other allergens (2.5%) administered alone or, in
a minimal percentage, in mixture.Patients’ survey
Knowledge
Almost 3 out of 4 patients claimed to have heard of SIT for
the first time from a physician (48.4% from a specialist and
24.4% from a GP), 14.6% from their relatives and 8.6% from
the mass media (4% did not remember). Accordingly,
patients’ current knowledge on SIT was acquired through
the information given by the specialist (86.3%), the GP
(8.7%), some friends (3.1%) and the media (1.9%).
With regard to treatment effect, 7.9% of patients
believed it to be immediate, 31.5% thought it would start
after a few months, 28.5% after one year, 26.5% after 2
years while 5.6% declared they did not know. The majority
of patients (70.6%) believed that SIT should be continued
for more than two years, while lower percentages of
patients indicated shorter periods (only a few months
(1.4%), one year (4.2%), two years (13%), respectively)
while 10.8% declared they had no idea how long the
treatment would last.
Concerning their knowledge of the properties of SIT,
38.4% of patients expected it to cause side effects, 35%
believed it could prevent the development of new allergies
and 15.2% thought it would be necessary to stop other anti-
allergy medications.
Perceptions
When asked to evaluate the relevance of their physician’s
opinion in their choice of starting with SIT on a 0e100 VAS,
the patients gave a mean score of 82 (SD 21.03). Patients’
perceptions regarding SIT treatment properties are
summarized in Table 2.
Moreover, 2.3% of patients reported that SIT caused
them severe side effects, 19% reported annoying but not
severe side effects, while the remainder had no side effects
related to SIT.
As for additional pharmacotherapy, 81.5% of patients
declared they used fewer anti-allergy drugs once they
started immunotherapy, and 35% thought the benefits
exceeded the costs. Almost all patients reported an
improvement of their allergic condition since they started
SIT (Table 3).
Expectations
Most patients expected, when starting with SIT, that it
would help them to recover from their allergy (38.1%),
HRQoL improvement (21.4%), symptoms reduction (22.6%),
lower consumption of anti-allergy medication (10.5%)
worsening avoidance (6.4%) while 1% of patients did not
specify their expectations. Using a 0e100 VAS, patients
expected an overall SIT success rate of 83.4 (SD 13.8, VAS-
score range 35e100) and rated their level of confidence in
SIT by on mean 77.7 (SD 21.3, VAS-score range 0e100).
Satisfaction
The mean satisfaction degree for SIT effects with regard to
symptoms was 74 (SD 21.5; VAS-score range 0e100), and the












SIT is safe 54.5 37.4 0.2 0.2 7.7
SIT is easy to take 68.6 27.4 0.5 0 3.5
SIT is handy to use
in daily routine
47.2 42.7 1.8 0.2 8.1
It is easy to remember
to take SIT
50.8 37 2.8 0.2 9.2
SIT allows to better
control your allergy
56 35.2 0.7 5.1 3
364 I. Baiardini et al.mean global satisfaction degree for the treatment was 77.7
(SD 21.3; VAS-score range 0e100).
No difference in the degree of satisfaction was noticed
between mono- and poly-sensitized patients. The vast
majority of patients (81.5%) declared they used fewer anti-
allergic medication since the start of SIT. Based on their
personal experience, the majority of patients (60.7%) were
convinced they would “surely start SIT again”, 32.2%
answered “I would probably start”, while 2.3% would not
engage on treatment with SIT again and 4.7% did not specify
their answer. With regard to the administration modality,
38.4% of patients would like to change it, 39.6% would not
and 22% did not answer.
Differences in answers based on patients’
educational level
For this subgroup analysis, patients were divided into two
groups according to their educational level (high or low) at
the start of the survey. In the entire survey, only for the
question “In your opinion, can SIT prevent the development
of new allergies?” an association between education level
was found (Chi Square 4409, pZ 0.029) where a higher
percentage of patients with a high education agreed with
this statement (64% vs. 53%).
Difference in answers between the two SIT
formulations (SCIT versus SLIT)
The majority of patients were taking SLIT (313, 74%) while
110 patients were administered SCIT. For some questions
statistically significant associations were found betweenTable 3 Patients’ and physicians’ perceptions of change





Much worse 1.4 0.2
Worse 1.2 0.2
A bit worse 0.8 0.2
No change 4 3.8
A bit better 17.6 20.4
Better 42 57.9
Much better 33 17.3the treatment groups. A significantly higher percentage of
patients treated with SLIT, compared to those with SCIT,
reported that SIT is easy to take (Chi Square 5.772,
pZ 0.016), does not induce side effects (Chi Square 5.205
pZ 0.023), can prevent the development of new allergies
(Chi Square 10.952, p< 0.001) and that the benefits ob-
tained with this treatment exceed its costs (Chi Square
4.491, pZ 0.034), while a higher percentage of patients
treated with SCIT preferred to change the administration
mode of their SIT (Chi Square 39.076, p< 0.0001).
A subgroup analysis based on the different allergens
used for SIT was not possible due to too low numbers in one
or more subgroups.
Physicians’ answers
Physicians’ satisfaction score regarding SIT results was on
mean 77.7 (SD 16.3, VAS-range 5e100). The improvement in
allergy symptoms and signs was equally positive and similar
to the patient reported answers (Table 3). Over 90% of
physicians answered they would prescribe the same type of
SIT for that specific patient again (68% of them would surely
prescribe it, 27.5% probably) whereas 1.7% declared that
they would not (1.2% probably not and 0.5% surely not) and
2.8% did not know.
Concordance between patients’ and physicians’
answers
There was a significant correlation between patients’ and
physicians’ satisfaction scores regarding SIT, both in the
SCIT group (rZ 0.612, p< 0.001) and in the SLIT group
(rZ 0.608, p< 0.001) (Fig. 1).
Moreover, physicians and patients expressed a signifi-
cant level of agreement in judging the clinical changes
after starting SIT treatment, both in the SCIT group (Kap-
paZ 0.318, p< 0.001) and the SLIT group (KappaZ 0.380,
p< 0.001).
Discussion
This real life cross-sectional survey aimed to evaluate the
personal perspectives during treatment with either subcu-
taneous or sublingual SIT in a large number of Italian
patients recruited from various medical centres. To this
Figure 1 Correlation between patients’ and physicians’
satisfaction level (VAS-score) on subcutaneous (A; rZ 0.612,
p< 0.001) and sublingual (B; rZ 0.608, p< 0.001) SIT.
Patient evaluation of allergen-specific immunotherapy 365end, a survey consisting of 28 questions assessing patient’s
knowledge, perceptions, expectations and satisfaction was
developed by an expert panel. The survey was readily
accepted by the patients: 449 out of 455 decided to
participate, and, it was deemed easy to understand and to
complete. In addition, correspondence with the physician’s
view was assessed. Our data confirm and extend previously
published experience with SIT.8,10,14
Allergen-specific immunotherapy is a valuable causal
treatment for respiratory allergies. However, it is a lengthy
therapy and not without certain risks. Therefore, patient
knowledge should be adequate when following SIT therapy.
Although over 70% of patients showed adequate knowledge
of SIT, this survey identified some gaps and misconceptions
in patients, independent of their educational level.
Approximately 40% of the patients expected immediate
results from SIT, about one out of five patients wasconvinced that the treatment should be pursued for a short
period and 15% thought that SIT and regular pharmaco-
therapy are incompatible. Our findings are in agreement
with the results of Rathkopf et al.,14 who reported
adequate knowledge in 77% of 158 patients receiving aer-
oallergen and/or venom immunotherapy before the start of
therapy. On the other hand, Sade et al.,10 found “a serious”
lack of knowledge and numerous misconceptions among
substantial numbers of patients receiving aeroallergen
immunotherapy. Both these studies only evaluated SCIT.
Since the treating physician, and in particular the
specialist, represents the most important reference point
for all treatment information, a standard “check list” to
ensure patients receive all the required information before
engaging on SIT could help to minimize knowledge gaps and
misconceptions. Ensuring adequate knowledge and
personal evaluation on SIT for each patient both when
therapy is prescribed and during is crucial. It may prevent
misunderstandings and inadequate expectations and may
even increase compliance.15
When asked to indicate their degree of agreement with
a series of statements regarding their perceptions of SIT
treatment, the majority of patients were positive towards
integration of SIT in their everyday lives. More than 8
patients out of 10 considered SIT safe, easy to take, easy to
remember, feasible to integrate in daily routine, and
capable of improving allergy control. Other perceived
benefits by patients included a reduced use of anti-allergy
medications and an improvement of their allergic condition.
Regarding their expectations towards SIT, all patients
had high confidence that the treatment would successfully
affect several aspects of their allergic disorder.
Independently of the duration and the kind of SIT
modality, patients indicated a high level of satisfaction
with the effects of SIT, both on symptoms, need of addi-
tional medications and HRQoL. Similarly, the majority of
physicians also expressed a high level of satisfaction with
the efficacy of SIT, inducing relevant improvement. If
patients and physicians are of one mind concerning these
two relevant issues regarding treatment management, this
could help to build a real partnership favouring compliance
and treatment efficacy.16,17 Adequate monitoring of treat-
ment effect and sharing a long-time treatment plan
represent hard to reach objectives if physicians and
patients evaluate SIT benefits differently.
The comparison between patient’s evaluations of SLIT
and SCIT revealed that SLIT was frequently considered
easier to take and superior in terms of costs/benefits,
although a similar degree of satisfaction was reported in
both treatment groups.
Our study should be viewed in the light of its limitations.
The cross-sectional design, the use of self-report tools, the
differences in clinical and therapeutic aspects (including the
presence or absence of any co-sensitisations or concomitant
asthma, administration modality, treatment duration) can
be considered as themainweak points. Moreover, our results
refer to the patients’ personal point of view with regards to
a specific product and treatment regimen and thus cannot be
generalized to other SIT products or to other administration
modalities. We acknowledge that the correlation we found
between patient and physician satisfaction towards treat-
ment may be somewhat influenced by the doctorepatient
366 I. Baiardini et al.relationship. In patients with a chronic condition, the choice
of treatment by the treating physician may positively affect
the patient’s view and satisfaction towards this treatment.
Conversely, a patient’s satisfaction towards treatment will
positively affect the physician’s judgement. However,
patients and physicians scored the questions independently,
and since in our study strong correlations between patient
and physician satisfaction scores were found over the entire
VAS scale reflecting several aspects of satisfaction, we
believe this reinforces the positive value of our findings.
The main strength is that data collection was performed
in real life in a large patient population, providing relevant
data for clinicalmanagement of patients receiving SIT: this is
in accordance with the most recent guidelines, emphasizing
the importance of the patient’s point of view on treatment.
Our results can be considered as preliminary data that must
be followedby further research involving other countries and
longitudinal samples, before more solid conclusions can be
drawn regarding the patients’ viewpoint about SIT.Acknowledgements
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